Greg Kauffmann1, Stanley L Liauw2. 1. Department of Radiation and Cellular Oncology, University of Chicago, 5758 South Maryland Avenue MC 9006, Chicago, IL, 60637, USA. 2. Department of Radiation and Cellular Oncology, University of Chicago, 5758 South Maryland Avenue MC 9006, Chicago, IL, 60637, USA. sliauw@radonc.uchicago.edu.
Abstract
PURPOSE OF REVIEW: Androgen deprivation therapy (ADT) is an important adjunctive therapy to external beam radiation therapy (RT) for the definitive management of prostate cancer. The role of ADT is well-established for locally advanced or high-risk disease in conjunction with standard doses of RT, but less defined for intermediate-risk disease or with dose-escalated RT. The goal of this review is to summarize evidence evaluating the combination of ADT/RT, focusing on recent trials and current controversies as they pertain to the practicing clinician. RECENT FINDINGS: The benefit of ADT on biochemical control is maintained with dose-escalated RT according to recently reported phase III studies. Furthermore, there is now prospective, randomized evidence to support the addition of ADT to RT in the post-prostatectomy setting. ADT continues to play an important role for prostate cancer patients receiving dose-escalated RT. Future research is needed to identify subgroups most likely to benefit from this combination.
PURPOSE OF REVIEW: Androgen deprivation therapy (ADT) is an important adjunctive therapy to external beam radiation therapy (RT) for the definitive management of prostate cancer. The role of ADT is well-established for locally advanced or high-risk disease in conjunction with standard doses of RT, but less defined for intermediate-risk disease or with dose-escalated RT. The goal of this review is to summarize evidence evaluating the combination of ADT/RT, focusing on recent trials and current controversies as they pertain to the practicing clinician. RECENT FINDINGS: The benefit of ADT on biochemical control is maintained with dose-escalated RT according to recently reported phase III studies. Furthermore, there is now prospective, randomized evidence to support the addition of ADT to RT in the post-prostatectomy setting. ADT continues to play an important role for prostate cancerpatients receiving dose-escalated RT. Future research is needed to identify subgroups most likely to benefit from this combination.
Authors: Behfar Ehdaie; Coral L Atoria; Amit Gupta; Andrew Feifer; William T Lowrance; Michael J Morris; Peter T Scardino; James A Eastham; Elena B Elkin Journal: Cancer Date: 2011-11-09 Impact factor: 6.860
Authors: James W Denham; Allison Steigler; David S Lamb; David Joseph; Sandra Turner; John Matthews; Chris Atkinson; John North; David Christie; Nigel A Spry; Keen-Hun Tai; Chris Wynne; Catherine D'Este Journal: Lancet Oncol Date: 2011-05 Impact factor: 41.316
Authors: Richard K Valicenti; Kwounghwa Bae; Jeff Michalski; Howard Sandler; William Shipley; Alex Lin; James Cox Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-01 Impact factor: 7.038
Authors: S L Goldenberg; L H Klotz; J Srigley; M A Jewett; D Mador; Y Fradet; J Barkin; J Chin; J M Paquin; M J Bullock; S Laplante Journal: J Urol Date: 1996-09 Impact factor: 7.450
Authors: Vinayak Muralidhar; Meredith M Regan; Lillian Werner; Mari Nakabayashi; Carolyn P Evan; Joaquim Bellmunt; Toni K Choueiri; Aymen A Elfiky; Lauren C Harshman; Rana R McKay; Mark M Pomerantz; Christopher J Sweeney; Mary-Ellen Taplin; Philip W Kantoff; Paul L Nguyen Journal: Clin Genitourin Cancer Date: 2015-12-17 Impact factor: 2.872
Authors: Gregory P Swanson; Michael A Hussey; Catherine M Tangen; Joseph Chin; Edward Messing; Edith Canby-Hagino; Jeffrey D Forman; Ian M Thompson; E David Crawford Journal: J Clin Oncol Date: 2007-06-01 Impact factor: 44.544